{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,9]],"date-time":"2026-03-09T23:21:52Z","timestamp":1773098512851,"version":"3.50.1"},"reference-count":55,"publisher":"MDPI AG","issue":"18","license":[{"start":{"date-parts":[[2022,9,9]],"date-time":"2022-09-09T00:00:00Z","timestamp":1662681600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Ekhaga Foundation"},{"name":"Osmond Foundation"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["IJERPH"],"abstract":"<jats:p>Objectives: Absenteeism from work due to illness, and related costs, has increased steadily during the past decades. In recent years, there has been a reemergence of research on the therapeutic effects of classic psychedelics showing associations with both physical and mental health. However, the association between classic psychedelics and sick leave remains unknown. The aim of this study is to investigate the association between lifetime classic psychedelic use and sick leave in the past 30 days among adults in the United States (N = 407,717), using data from the National Survey on Drug Use and Health (2005\u20132019), weighted to be representative of the US adult population. Methods: The primary analysis was conducted using multiple linear regression, controlling for sociodemographic characteristics, risky behavior, and use of other substances. Results: There was a significant and negative association between lifetime classic psychedelic use and sick leave in the past 30 days (B = \u22120.09, p &lt; 0.01) when adjusting for all control variables. Conclusion: These findings suggest that classic psychedelics could potentially lead to reduced sick leave and associated costs in the general population, but more research is needed to investigate potential causal pathways of classic psychedelics on sick leave and evaluate possible mechanisms.<\/jats:p>","DOI":"10.3390\/ijerph191811353","type":"journal-article","created":{"date-parts":[[2022,9,12]],"date-time":"2022-09-12T22:53:46Z","timestamp":1663023226000},"page":"11353","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":14,"title":["Association between Lifetime Classic Psychedelic Use and Sick Leave in a Population-Based Sample"],"prefix":"10.3390","volume":"19","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0778-2776","authenticated-orcid":false,"given":"Christin","family":"Mellner","sequence":"first","affiliation":[{"name":"Department of Psychology, Stockholm University, 114 19 Stockholm, Sweden"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Micael","family":"Dahlen","sequence":"additional","affiliation":[{"name":"Stockholm School of Economics, 114 19 Stockholm, Sweden"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4197-7566","authenticated-orcid":false,"given":"Otto","family":"Simonsson","sequence":"additional","affiliation":[{"name":"Department of Clinical Neuroscience, Karolinska Institutet, 171 77 Stockholm, Sweden"},{"name":"Department of Sociology, University of Oxford, Oxford OX1 1JD, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2022,9,9]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"925","DOI":"10.1086\/529000","article-title":"Disease and Development: The Effect of Life Expectancy on Economic Growth","volume":"115","author":"Acemoglu","year":"2007","journal-title":"J. Political Econ."},{"key":"ref_2","first-page":"766","article-title":"Health, Nutrition, and Economic Development","volume":"36","author":"Strauss","year":"1998","journal-title":"J. Econ. Litt."},{"key":"ref_3","first-page":"1","article-title":"Investment in Human Capital","volume":"15","author":"Schultz","year":"1961","journal-title":"Am. Econ. Rev."},{"key":"ref_4","first-page":"319","article-title":"Longevity and Life-Cycle Savings","volume":"105","author":"Bloom","year":"2003","journal-title":"Swed. J. Econ."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1007\/s10198-005-0303-4","article-title":"Indirect Costs of Cervical and Breast Cancers in Spain","volume":"6","author":"Oliva","year":"2005","journal-title":"Eur. J. Health Econ."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"1005","DOI":"10.1016\/0277-9536(92)90131-9","article-title":"Towards a New Approach for Estimating Indirect Costs of Disease","volume":"34","author":"Koopmanschap","year":"1992","journal-title":"Soc. Sci. Med."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1002\/nur.20461","article-title":"Work Productivity and Health of Informal Caregivers of Persons with Advanced Cancer","volume":"34","author":"Mazanec","year":"2011","journal-title":"Res. Nurs. Health"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/j.healthpol.2005.07.016","article-title":"Cost-of-Illness Analysis: What Room in Health Economics?","volume":"77","author":"Tarricone","year":"2006","journal-title":"Health Policy"},{"key":"ref_9","unstructured":"CDC Foundation (2022, May 28). Worker Illness and Injury Cost U.S Employers $ 225.8 Billion Annually. Available online: https:\/\/www.cdcfoundation.org\/pr\/2015\/worker-illness-and-injury-costs-us-employers-225-billion-annually."},{"key":"ref_10","unstructured":"Integrated Benefits Institute (2022, May 28). Cost of Poor Health Infographic Data (2019 Data). Available online: https:\/\/www.ibiweb.org\/resources\/cost-of-poor-health-infographic-2019-data."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"39","DOI":"10.18778\/0208-6018.333.03","article-title":"Determinants of Employee Absence Differentiation","volume":"1","author":"Striker","year":"2018","journal-title":"Folia Oeconomica"},{"key":"ref_12","first-page":"1","article-title":"NHS Sickness Absence in England: Hidden Patterns","volume":"26","author":"Jones","year":"2020","journal-title":"Br. J. Hosp. Med."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1093\/eurpub\/cks183","article-title":"Gender Difference in Sickness Absence from Work: A Multiple Mediation Analysis of Psychosocial Factors","volume":"23","author":"Casini","year":"2013","journal-title":"Eur. J. Public Health"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1136\/jech.2003.011817","article-title":"Sickness Absence as a Predictor of Mortality among Male and Female Employees","volume":"58","author":"Vahtera","year":"2004","journal-title":"J. Epidemiol. Community Health"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1080\/02813432.2019.1568710","article-title":"Determinants of Sickness Absence Rate among Finnish Municipal Employees","volume":"37","author":"Vuorio","year":"2019","journal-title":"Scand. J. Prim. Health Care"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1093\/occmed\/kqy062","article-title":"Explaining the Gender Gap in Sickness Absence","volume":"68","author":"Mykletun","year":"2018","journal-title":"Occup. Med."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1001\/jamapsychiatry.2020.2171","article-title":"The current status of psychedelics in psychiatry","volume":"78","author":"Nutt","year":"2021","journal-title":"JAMA Psychiatry"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"1058","DOI":"10.1177\/0269881119827796","article-title":"Prevalence and epidemiological associates of novel psychedelic use in the United States adult population","volume":"33","author":"Sexton","year":"2019","journal-title":"J. Psychopharmacol."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"1558","DOI":"10.1016\/S0140-6736(10)61462-6","article-title":"Drug harms in the UK: A multicriteria decision analysis","volume":"376","author":"Nutt","year":"2010","journal-title":"Lancet"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1124\/pr.115.011478","article-title":"Psychedelics","volume":"68","author":"Nichols","year":"2016","journal-title":"Pharmacol. Rev."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1177\/0269881114565144","article-title":"Psilocybin-assisted treatment for alcohol dependence: A proof-of-concept study","volume":"29","author":"Bogenschutz","year":"2015","journal-title":"J. Psychopharmacol."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1016\/j.neuropharm.2018.05.012","article-title":"The abuse potential of medical psilocybin according to the 8 factors of the Controlled Substances Act","volume":"142","author":"Johnson","year":"2018","journal-title":"Neuropharmacology"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"606","DOI":"10.1177\/0269881117691453","article-title":"The association of psychedelic use and opioid use disorders among illicit users in the United States","volume":"31","author":"Pisano","year":"2017","journal-title":"J. Psychopharmacol."},{"key":"ref_24","unstructured":"Bogenschutz, M.P., Ross, S., and Bhatt, S. (2022). Psychotherapy vs placebo in the treatment of adult patients with alcohol use disorder. A randomized controlled trial. JAMA Psychiatry."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1080\/09540261.2018.1481827","article-title":"Psychedelics as anti-inflammatory agents","volume":"30","author":"Flanagan","year":"2018","journal-title":"Int. Rev. Psychiatry"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"35","DOI":"10.3389\/fphar.2016.00035","article-title":"The therapeutic potentials of ayahuasca: Possible effects against various diseases of civilization","volume":"7","author":"Frecska","year":"2016","journal-title":"Front. Pharm."},{"key":"ref_27","unstructured":"Michael, J.W., and Ben, S. (2019). Effects of psychedelics on inflammation and immunity. Advances in Psychedelic Medicine: State-of-the-Art Therapeutic Applications, ABC-CLIO."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"889","DOI":"10.1080\/17512433.2018.1511424","article-title":"Efficacy, tolerability, and safety of serotonergic psychedelics for the management of mood, anxiety, and substance-use disorders: A systematic review of systematic reviews","volume":"11","author":"Bouso","year":"2018","journal-title":"Expert Rev. Clin. Pharm."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1016\/j.neuropharm.2017.12.040","article-title":"Psychiatry & the psychedelic drugs. Past, present & future","volume":"142","author":"Rucker","year":"2018","journal-title":"Neuropharmacology"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1016\/j.neubiorev.2020.03.017","article-title":"Long-term effects of psychedelic drugs: A systematic review","volume":"113","author":"Aday","year":"2020","journal-title":"Neurosci. Biobehav. Rev."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1016\/S2215-0366(16)30065-7","article-title":"Psilocybin with psychological support for treatment-resistant depression: An open-label feasibility study","volume":"3","author":"Bolstridge","year":"2016","journal-title":"Lancet Psychiatry"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1007\/s00213-017-4771-x","article-title":"Psilocybin with psychological support for treatment-resistant depression: Six-month follow-up","volume":"235","author":"Bolstridge","year":"2018","journal-title":"Psychopharmacology"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1001\/jamapsychiatry.2020.3285","article-title":"Effects of psilocybin-assisted therapy on major depressive disorder. A randomized clinical trial","volume":"78","author":"Davis","year":"2021","journal-title":"JAMA Psychiatry"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"2655","DOI":"10.1017\/S003329172000389X","article-title":"Post-acute psychological effects of classical serotonergic psychedelics: A systematic review and meta-analysis","volume":"50","author":"Goldberg","year":"2020","journal-title":"Psychol. Med."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"983","DOI":"10.1177\/0269881114548296","article-title":"Pilot study of the 5-HT2AR agonist psilocybin in the treatment of tobacco addiction","volume":"28","author":"Johnson","year":"2014","journal-title":"J. Psychopharmacol."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1080\/02791072.2020.1769878","article-title":"A Meta-Analysis of Placebo-Controlled Trials of Psychedelic-Assisted Therapy","volume":"52","author":"Luoma","year":"2020","journal-title":"J. Psychoact. Drugs"},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1177\/0269881117735685","article-title":"The relationships of classic psychedelic use with criminal behavior in the United States adult population","volume":"32","author":"Hendricks","year":"2018","journal-title":"J. Psychopharmacol."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"4099","DOI":"10.1038\/s41598-022-08085-4","article-title":"Associations between classic psychedelics and opioid use dirsorder in a nationally-representative U.S. adult sample","volume":"12","author":"Jones","year":"2022","journal-title":"Sci. Rep."},{"key":"ref_39","doi-asserted-by":"crossref","unstructured":"Krebs, T.S., and Johansen, P.\u00d8. (2013). Psychedelics and mental health: A population study. PLoS ONE, 8.","DOI":"10.1371\/journal.pone.0063972"},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"98","DOI":"10.12688\/f1000research.2-98.v1","article-title":"Over 30 million psychedelic users in the United States","volume":"2","author":"Krebs","year":"2013","journal-title":"F1000Research"},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1177\/0269881121996863","article-title":"Associations between lifetime classic psychedelics use and markers of physical health","volume":"35","author":"Simonsson","year":"2021","journal-title":"J. Psychopharmacol."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"1510","DOI":"10.1161\/HYPERTENSIONAHA.120.16715","article-title":"Association Between Lifetime Classic Psychedelic Use and Hypertension in the Past Year","volume":"77","author":"Simonsson","year":"2021","journal-title":"Hypertension"},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"14427","DOI":"10.1038\/s41598-021-93787-4","article-title":"Associations between lifetime classic psychedelics use and cardiometabolic diseases","volume":"11","author":"Simonsson","year":"2021","journal-title":"Sci. Rep."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"1088","DOI":"10.1177\/0269881119845793","article-title":"Cessation and reduction in alcohol consumption and misuse after psychedelic use","volume":"33","author":"Davis","year":"2019","journal-title":"J. Psychopharmacol."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1080\/02791072.2019.1567961","article-title":"Ayahuasca and public health: Health status, psychosocial well-being, lifestyle, and coping strategies in a large sample of ritual ayahuasca users","volume":"51","author":"Ona","year":"2019","journal-title":"J. Psychoact. Drugs"},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1177\/02698811211008554","article-title":"Psychedelics and health behaviour change","volume":"36","author":"Teixeira","year":"2021","journal-title":"J. Psychopharmacol."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1177\/0022167817709585","article-title":"Patients\u2019 accounts of increased \u201cconnectedness\u201d and \u201cacceptance\u201d after psilocybin for treatment-resistant depression","volume":"57","author":"Watts","year":"2017","journal-title":"J. Humanist. Psychol."},{"key":"ref_48","doi-asserted-by":"crossref","unstructured":"Lund, I., Moan, I.S., and Edvardsen, H.M.E. (2019). The relative impact of smoking, alcohol use and drug use on general sickness absence among Norwegian employees. BMC Public Health, 19.","DOI":"10.1186\/s12889-019-6891-1"},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1080\/14034950410021853","article-title":"Risk factors for sick leave\u2013General studies","volume":"32","author":"Allebeck","year":"2005","journal-title":"Scand. J. Public Health"},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1177\/0269881117731279","article-title":"Psilocybin-occasioned mystical-type experience in combination with meditation and other spiritual practices produces enduring positive changes in psychological functioning and in trait measures of prosocial attitudes and behaviors","volume":"32","author":"Griffiths","year":"2018","journal-title":"J. Psychopharmacol."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"1161","DOI":"10.1007\/s00213-019-05445-3","article-title":"Ayahuasca\u2019s \u2018afterglow\u2019: Improved mindfulness and cognitive flexibility in ayahuasca drinkers","volume":"237","author":"Soar","year":"2020","journal-title":"J. Psychopharmacol."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"1145","DOI":"10.1016\/j.amjmed.2016.05.018","article-title":"Mental health and cardiovascular disease","volume":"129","author":"Chaddha","year":"2016","journal-title":"Am. J. Med."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"109406","DOI":"10.1016\/j.mehy.2019.109406","article-title":"The Psilocybin-Telomere Hypothesis: An empirically falsifiable prediction concerning the beneficial neuropsychopharmacological effects of psilocybin on genetic aging","volume":"134","author":"Germann","year":"2020","journal-title":"Med. Hypoth."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1177\/1754073917697824","article-title":"Psychological well-being and physical health: Associations, mechanisms, and future directions","volume":"10","author":"Hernandez","year":"2018","journal-title":"Emot. Rev."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1177\/0091450919884739","article-title":"(Re)conceptualizing \u201cpolydrug use\u201d: Capturing the complexity of combining substances","volume":"46","author":"Hakkarainen","year":"2019","journal-title":"Contemp. Drug Probl."}],"container-title":["International Journal of Environmental Research and Public Health"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1660-4601\/19\/18\/11353\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T00:28:30Z","timestamp":1760142510000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1660-4601\/19\/18\/11353"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,9,9]]},"references-count":55,"journal-issue":{"issue":"18","published-online":{"date-parts":[[2022,9]]}},"alternative-id":["ijerph191811353"],"URL":"https:\/\/doi.org\/10.3390\/ijerph191811353","relation":{},"ISSN":["1660-4601"],"issn-type":[{"value":"1660-4601","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,9,9]]}}}